- Home
- GROW vs RVPH Comparison
GROW vs RVPH Comparison
Compare GROW & RVPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GROW | RVPH |
|---|---|---|
| Founded | 1968 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 32.2M | 71.0M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | GROW | RVPH |
|---|---|---|
| Price | $2.47 | $0.66 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $3.33 |
| AVG Volume (30 Days) | 45.0K | ★ 4.4M |
| Earning Date | 11-12-2025 | 11-13-2025 |
| Dividend Yield | ★ 3.70% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.07 | N/A |
| Revenue | ★ $8,546,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $37.27 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.02 | $0.25 |
| 52 Week High | $2.78 | $2.95 |
Technical Indicators
Market Signals| Indicator | GROW | RVPH |
|---|---|---|
| Relative Strength Index (RSI) | 49.21 | 58.18 |
| Support Level | $2.36 | $0.60 |
| Resistance Level | $2.50 | $0.77 |
| Average True Range (ATR) | 0.08 | 0.05 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 54.90 | 61.01 |
Price Performance
Historical ComparisonAbout GROW U.S. Global Investors Inc.
US Global Investors Inc is a registered investment advisory firm. The company manages the following business segments: Investment management services; through which the company offers, to U.S. Global Investors Funds (USGIF or the Funds) and exchange-traded fund (ETF) clients, a range of investment management products and services to meet the needs of individual and institutional investors; and Corporate Investments, through which the company invests for its own account in an effort to add growth and value to its cash position. It derives all its revenue from Investment management services.
About RVPH Reviva Pharmaceuticals Holdings Inc.
Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease and Parkinson's disease psychosis and its other drug candidate is RP1208.